Ticker

WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences:

On track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials  Part A readouts from SKYLINE platform trial in ulcerative colitis ("UC") expected to begin in the second quarter, with enrollment continuing ahead of schedule Enrollment on track in Phase 2 SKYWAY basket trial evaluating TL1A inhibition in rheumatoid arthritis ("RA"), psoriatic arthritis ("PsA"), and axial…

WALTHAM, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease and rheumatic diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of…

Spyre Therapeutics, Inc. (NASDAQ: SYRE - Get Free Report) was the target of a large drop in short interest in the month of January. As of January 15th, there was short interest totaling 10,069,741 shares, a drop of 13.5% from the December 31st total of 11,636,998 shares. Approximately 13.8% of the company's shares are short sold.

Spyre Therapeutics, Inc. (NASDAQ: SYRE - Get Free Report) has received an average rating of "Buy" from the ten brokerages that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, six have issued a buy rating and three have given a strong buy rating to the company.